Regulatory press release03.12.2025 klo 19.55Lipigon Pharmaceuticals presents top-line data from the Phase II clinical trial of Lipisense in patients with elevated blood lipid levels
Press release14.10.2025 klo 23.58Lipigon Pharmaceuticals reports last patient visit in the three-month follow-up of its Phase II clinical study with Lipisense
Regulatory press release06.07.2025 klo 10.03Lipigon Pharmaceuticals Enrolls Last Patient in Phase II Study with Lipisense®
Press release27.05.2025 klo 09.36Redeye: Lipigon Q1 2025 - 64.5% Subscription Rate in the Rights Issue
Regulatory press release20.03.2025 klo 13.15Lipigon Pharmaceuticals' commercial partner announces positive results from Phase I clinical trial with Lipisense
Regulatory press release21.11.2024 klo 11.00Första patienten doserad i Lipigon Pharmaceuticals kliniska fas II-studie med Lipisense®
Press release18.09.2024 klo 13.51Lipigon's development partner Leaderna Therapeutics reports last person treated in ongoing Phase 1 study with Lipisense®
Regulatory press release09.07.2024 klo 15.00Lipigon Receives Milestone Payment of USD 1 Million from Leaderna for Approval of Phase I Bridging Study
Press release20.06.2024 klo 09.30New Publication: The ANGPTL4 Protein May Reduce the Risk of Cardiovascular Disease and Diabetes
Press release15.05.2024 klo 09.28Lipigon and Leaderna Collaboration on Lipisense® Shows Good Progress
Regulatory press release14.05.2024 klo 08.53Lipigon collaborates with University of Washington on lung damage project
Press release07.02.2024 klo 17.00The Swedish Medical Products Agency approves Lipigon's phase II study with Lipisense®